Bond.az White LogoBond.az Black Logo

Newcleo to Go Public via SPAC Merger at $2.4B Valuation

Newcleo merges with SPAC NewHold at $2.4B valuation, lists on Nasdaq as NWCL. PIPE of $220M included. Transaction expected to close in 2026.

Aria Wright
ByAria Wright- Senior Editor
|
0

PARIS and NEW YORK - Newcleo Ltd., a nuclear energy company developing lead-cooled fast reactors and mixed oxide fuel, announced today it has entered into a definitive agreement to merge with NewHold Investment Corp III (NASDAQ:NHIC).

The transaction values Newcleo at a pre-money equity value of approximately $2.4 billion and is expected to provide up to $429 million in gross proceeds from a combination of $220 million in PIPE and up to $209 million of cash held in NewHold's trust account.

NewHold's stock surged 12.5% over the past week ahead of the announcement. The combined company is expected to list on the Nasdaq under the ticker NWCL, with the transaction closing in the second half of 2026.

Founded in 2021, Newcleo operates in seven countries with over 900 employees and generated approximately $80 million in revenue in 2024. The company has raised about $780 million in private funds since its founding.

Newcleo is developing 200MWe commercial reactor designs and MOX fuel produced from reprocessed nuclear waste. The company has a joint venture with JAVYS in Slovakia to deploy up to four reactors at the Bohunice site.

In October 2025, Newcleo partnered with Oklo Inc. to build advanced fuel manufacturing infrastructure in the U.S. The transaction is subject to shareholder and regulatory approvals.

More News
Today / 11:36
|
615

ProLogium SPAC Merger Valued at $3.8B

ProLogium, a solid-state battery manufacturer, goes public via SPAC merger at $3.8 billion valuation on Nasdaq.

0
Today / 11:33
|
285

Erdene publishes 2026 shareholder letter, schedules meeting

Erdene Resource Development Corp. published its 2026 shareholder letter and scheduled its annual meeting. Details on the Bayan Khundii gold mine operations.

0
Today / 09:02
|
855

FP-001 42 mg Clinical Trial Completed

Foresee Pharmaceuticals completes Phase 3 trial for FP-001 42 mg for precocious puberty. FDA submission planned for 2026. CAMCEVI 21mg approved in Europe.

0
Today / 07:05
|
446

Eden Research director resigns

Eden Research non-executive director Derek McAllan resigns due to ill health. Rob Cridland appointed interim Audit Committee chair.

0
Today / 06:31
|
362

HgCapital Trust invests £11m in Rightsline software

HgCapital Trust invests £11 million in Rightsline, a rights and royalties management software provider, as part of a $500M growth round.

0
Today / 01:32
|
429

Junshi Biosciences completes phase III lung cancer study

Junshi Biosciences completes phase III lung cancer study. Toripalimab combination shows promising results in resectable stage II-III NSCLC.

0
Yesterday / 21:31
|
985

Cheniere $2B Senior Notes Pricing

Cheniere Energy Partners prices $2 billion senior notes offering in two tranches with maturities in 2036 and 2056.

0
Yesterday / 19:01
|
244

Healthpeak Properties Stock Hits 52-Week High

Healthpeak Properties stock hits 52-week high of $19.94. Annual return 26%, dividend yield 6.2%. Q1 EPS beats estimates by 369%.

0
Yesterday / 19:00
|
392

Arbor Realty Trust Stock Hits 52-Week Low at $5.48

Arbor Realty Trust stock hits 52-week low at $5.48. RSI oversold, dividend yield 12.21%. Bond.az analysis suggests undervaluation.

0
Yesterday / 18:02
|
692

Ormat Technologies Stock Hits Record High

Ormat Technologies stock hits all-time high at $138.53. 90.59% annual surge, strong Q1 earnings, and renewable energy leadership insights.

0
Yesterday / 18:01
|
793

Hutchmed stock hits 52-week low at 11.7 USD

Hutchmed stock hits 52-week low at $11.70. P/E 4.64, fair value $14.06. Strong oncology earnings from HUTCHMED.

0
Yesterday / 17:32
|
580

TestEquity Names 5 Senior Executives

TestEquity appoints five senior executives and promotes its Mexico head to drive growth strategy. Find out more.

0
...